{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:09:32Z","timestamp":1786975772061,"version":"build-2736575974"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"DOI":"10.1001\/jamaoncol.2018.3267","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T21:41:10Z","timestamp":1534801270000},"page":"e183267","source":"Crossref","is-referenced-by-count":85,"title":["Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma"],"prefix":"10.1001","volume":"4","author":[{"given":"Ajay K.","family":"Nooka","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael (Luhua)","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooeun","family":"Bae","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Peterkin","sequence":"additional","affiliation":[{"name":"OncoPep Inc, North Andover, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"cbr180012r1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nyas.2016.1364.issue-1","article-title":"Multiple myeloma in the marrow: pathogenesis and treatments.","volume":"1364","author":"Fairfield","year":"2016","journal-title":"Ann N Y Acad Sci"},{"issue":"36","key":"cbr180012r2","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1038\/onc.2014.403","article-title":"The tumor microenvironment shapes hallmarks of mature B-cell malignancies.","volume":"34","author":"Shain","year":"2015","journal-title":"Oncogene"},{"key":"cbr180012r3","doi-asserted-by":"crossref","first-page":"198539","DOI":"10.1155\/2014\/198539","article-title":"Immunological dysregulation in multiple myeloma microenvironment.","volume":"2014","author":"Romano","year":"2014","journal-title":"Biomed Res Int"},{"key":"cbr180012r4","doi-asserted-by":"publisher","first-page":"157496","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression.","volume":"2012","author":"Manier","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"12","key":"cbr180012r5","doi-asserted-by":"publisher","first-page":"e970914","DOI":"10.4161\/21624011.2014.970914","article-title":"Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.","volume":"3","author":"Bae","year":"2014","journal-title":"Oncoimmunology"},{"issue":"17","key":"cbr180012r6","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1158\/1078-0432.CCR-11-2776","article-title":"Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.","volume":"18","author":"Bae","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"cbr180012r7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/leu.2014.159","article-title":"A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients.","volume":"29","author":"Bae","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"cbr180012r8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/leu.2017.316","article-title":"Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.","volume":"32","author":"Bae","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"cbr180012r9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity.","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"18","key":"cbr180012r10","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"5","key":"cbr180012r11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"cbr180012r12","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-018-0062-8","article-title":"Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.","author":"Bae","year":"2018","journal-title":"Leukemia"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2696714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T12:11:11Z","timestamp":1544703071000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.3267"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.3267","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,13]]}}}